StockMacro
Menu

Treace Medical Concepts

$4.31 +52% in 6 monthsMarket cap $282.6M

TMCI on XNAS, Health Care, Treace Medical Concepts, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 65% in 12 months but revenue fell 7.1% and the company lost $55.8M.

  • BadFree cash flow negative $18.6M over 12 months against $60M debt

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
450
Website
treace.com
Listed
Nasdaq, US
Last results
6 Nov 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $48.3M, net loss $12.6M.
Quarter to 31 Dec 2021: revenue $33.4M, net income -$6.6MQuarter to 31 Dec 2021: revenue $33.4M, net income -$6.6MQuarter to 31 Mar 2022: revenue $29.0M, net income -$9.0MQuarter to 31 Mar 2022: revenue $29.0M, net income -$9.0MQuarter to 30 Jun 2022: revenue $30.0M, net income -$17.2MQuarter to 30 Jun 2022: revenue $30.0M, net income -$17.2MQuarter to 30 Sep 2022: revenue $33.1M, net income -$12.1MQuarter to 30 Sep 2022: revenue $33.1M, net income -$12.1MQuarter to 31 Dec 2022: revenue $49.8M, net income -$4.4MQuarter to 31 Dec 2022: revenue $49.8M, net income -$4.4MQuarter to 31 Mar 2023: revenue $42.2M, net income -$13.5MQuarter to 31 Mar 2023: revenue $42.2M, net income -$13.5MQuarter to 30 Jun 2023: revenue $42.0M, net income -$12.3MQuarter to 30 Jun 2023: revenue $42.0M, net income -$12.3MQuarter to 30 Sep 2023: revenue $40.8M, net income -$17.5MQuarter to 30 Sep 2023: revenue $40.8M, net income -$17.5MQuarter to 31 Dec 2023: revenue $62.2M, net income -$6.3MQuarter to 31 Dec 2023: revenue $62.2M, net income -$6.3MQuarter to 31 Mar 2024: revenue $51.1M, net income -$18.7MQuarter to 31 Mar 2024: revenue $51.1M, net income -$18.7MQuarter to 30 Jun 2024: revenue $44.5M, net income -$21.2MQuarter to 30 Jun 2024: revenue $44.5M, net income -$21.2MQuarter to 30 Sep 2024: revenue $45.1M, net income -$15.4MQuarter to 30 Sep 2024: revenue $45.1M, net income -$15.4MQuarter to 31 Dec 2024: revenue $68.7M, net income -$501KQuarter to 31 Dec 2024: revenue $68.7M, net income -$501KQuarter to 31 Mar 2025: revenue $52.6M, net income -$15.9MQuarter to 31 Mar 2025: revenue $52.6M, net income -$15.9MQuarter to 30 Jun 2025: revenue $47.4M, net income -$17.4MQuarter to 30 Jun 2025: revenue $47.4M, net income -$17.4MQuarter to 30 Sep 2025: revenue $50.2M, net income -$16.3MQuarter to 30 Sep 2025: revenue $50.2M, net income -$16.3MQuarter to 31 Dec 2025: revenue $62.5M, net income -$9.4MQuarter to 31 Dec 2025: revenue $62.5M, net income -$9.4MQuarter to 31 Mar 2026: revenue $47.2M, net income -$18.0MQuarter to 31 Mar 2026: revenue $47.2M, net income -$18.0MQuarter to 30 Jun 2026: revenue $45.4M, net income -$15.9MQuarter to 30 Jun 2026: revenue $45.4M, net income -$15.9MQuarter to 30 Sep 2026: revenue $48.3M, net income -$12.6MQuarter to 30 Sep 2026: revenue $48.3M, net income -$12.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $68.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$48.3M-$12.6M
30 Jun 2026$45.4M-$15.9M
31 Mar 2026$47.2M-$18.0M
31 Dec 2025$62.5M-$9.4M
30 Sep 2025$50.2M-$16.3M
30 Jun 2025$47.4M-$17.4M
31 Mar 2025$52.6M-$15.9M
31 Dec 2024$68.7M-$501K
30 Sep 2024$45.1M-$15.4M
30 Jun 2024$44.5M-$21.2M
31 Mar 2024$51.1M-$18.7M
31 Dec 2023$62.2M-$6.3M
30 Sep 2023$40.8M-$17.5M
30 Jun 2023$42.0M-$12.3M
31 Mar 2023$42.2M-$13.5M
31 Dec 2022$49.8M-$4.4M
30 Sep 2022$33.1M-$12.1M
30 Jun 2022$30.0M-$17.2M
31 Mar 2022$29.0M-$9.0M
31 Dec 2021$33.4M-$6.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $203.3M $218.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -7.1% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$55.8M -$50.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.85 -$0.80
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 79.6% 79.9% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -24.4% -22.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -27.4% -22.9% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -74.0% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$18.6M -$26.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $39.8M $57.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $60.0M $55.3M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $20.2M -$2.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.97 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.94
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.4 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 1.5 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.6 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Treace Medical ConceptsTMCI (this company) $282.6Mloss1.4-7.1%-27.4%
InfuSystemINFU $287.5M30.52.0+2.4%6.5%
NeuropaceNPCE $273.9Mloss2.9+8.9%-20.0%
SS Innovations InternationalSSII $254.9Mloss5.5+27%-31.5%
Orthofix MedicalOFIX $247.4Mloss0.30+2.1%-5.4%
OraSure TechnologiesOSUR $238.9Mloss2.1-7.5%-41.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$247K

bought $247K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-0.9%

114 13F filers vs 115

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

49%

32.0M shares held by 13F filers (30 Sep 2026) of 65.6M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

2.7%

1.8M shares sold short (30 Oct 2026) of 65.6M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.7

1.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-6.9%

1.9M shares sold short in the report before, 1.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

41%

41% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 43%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-3.9%

$48.3M vs $50.2M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-23%

$2.2M vs $2.8M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$1K

the 12 months before: $700K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $4.31 on 20 Nov 2026, +65% over 12 months (12-month range $1.20 to $5.34)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $1.4M in the last 12 months (the 12 months before: $125K).
Revenue per quarter. Revenue $48.3M in the latest quarter, -3.9% on a year earlier.
Capital spending per quarter. Capital spending $2.2M in the latest quarter, -23% on a year earlier.
Institutional holders (13F filers). 114 13F filers reported holding it in the latest 13F quarter, +0.9% on a year earlier.
Federal obligations. Federal obligations: $17K published in the last 12 months, -96% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
9 Apr 20268-K and other filingsDirector or officer change
9 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Dec 20258-K and other filingsA major agreement ended
6 Nov 20258-K and other filingsDirector or officer change
6 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Apr 20258-K and other filingsDirector or officer change
7 Apr 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 May 2024Sharp changeClustered insider buying: clustered insider buying (5 independent filers, 5 filing(s) in 30 days, value_usd total 3.7M)
5 Mar 2024Sharp changeQuarterly revenue change: quarterly revenue change, 62.2M vs usual 37.1M (2023-12-31); 1.3x the same period a year earlier
5 Mar 2024Sharp changeShort interest spike: short interest spike, 2.9M vs usual 1.5M (2024-02-15); 2.7x the same period a year earlier
13 Feb 2024Sharp changeShort interest spike: short interest spike, 2.8M vs usual 1.5M (2024-01-31); 1.7x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.5M (2023-12-29); 1.7x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 3.8M vs usual 1.5M (2023-11-15); 1.4x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 3.9M vs usual 1.5M (2023-10-31); 1.5x the same period a year earlier
13 Jun 20238-K and other filingsCompleted an acquisition or asset sale
23 Feb 20238-K and other filingsDirector or officer change
23 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
22 Nov 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 4 filing(s) in 30 days, value_usd total 664K)
15 Nov 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.9M vs usual 785K (2022-09-30); 6.2x the same period a year earlier
27 Sep 20228-K and other filingsDirector or officer change
27 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Aug 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.2M vs usual 460K (2022-06-30); 7.7x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 2.3M vs usual 794K (2022-07-15); 3.3x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 2.0M vs usual 722K (2022-06-30); 2.2x the same period a year earlier
3 May 20228-K and other filingsA major agreement ended
25 Feb 20228-K and other filingsDirector or officer change
25 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Nov 2021: -$3.8M published
Month from 1 Dec 2021: -$5.2M published
Month from 1 Jan 2022: -$2.5M published
Month from 1 Feb 2022: -$501K published
Month from 1 Mar 2022: -$474K published
Month from 1 May 2022: -$1.7M published
Month from 1 Jun 2022: -$700K published
Month from 1 Jul 2022: -$821K published
Month from 1 Aug 2022: -$3.8M published
Month from 1 Sep 2022: -$3.7M published
Month from 1 Oct 2022: -$3.0M published
Month from 1 Nov 2022: -$5.0M published
Month from 1 Dec 2022: -$7.1M published
Month from 1 Jan 2023: -$9.7M published
Month from 1 Feb 2023: -$3.2M published
Month from 1 Mar 2023: -$6.6M published
Month from 1 Apr 2023: -$8.2M published
Month from 1 May 2023: -$1.9M published
Month from 1 Jun 2023: -$28.9M published
Month from 1 Mar 2024: -$1.0M published
Month from 1 May 2024: $5.6M published
Month from 1 Jun 2024: $416K published
Month from 1 Aug 2024: $1.0M published
Month from 1 Sep 2024: $266K published
Month from 1 Mar 2025: $125K published
Month from 1 May 2026: $716K published
Month from 1 Jun 2026: $389K published
Month from 1 Aug 2026: $247K published
Revenue per quarter
Quarter ended 31 Dec 2020: $24.1M; public on 5 Mar 2022
Quarter ended 31 Dec 2021: $33.4M, +39% on a year earlier; public on 5 Mar 2022
Quarter ended 31 Mar 2022: $29.0M, +55% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $30.0M, +45% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $33.1M, +53% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $49.8M, +49% on a year earlier; public on 9 Mar 2023
Quarter ended 31 Mar 2023: $42.2M, +45% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $42.0M, +40% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $40.8M, +23% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $62.2M, +25% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $51.1M, +21% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $44.5M, +6.0% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $45.1M, +11% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $68.7M, +10% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $52.6M, +2.9% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $47.4M, +6.6% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $50.2M, +11% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $62.5M, -9.0% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $47.2M, -10% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $45.4M, -4.2% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $48.3M, -3.9% on a year earlier; public on 7 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $88K; public on 5 Mar 2022
Quarter ended 31 Dec 2021: $900K, +923% on a year earlier; public on 5 Mar 2022
Quarter ended 31 Mar 2022: $1.5M, +656% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $5.2M, +671% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $5.9M, +524% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $2.3M, +159% on a year earlier; public on 9 Mar 2023
Quarter ended 31 Mar 2023: $1.5M, -0.2% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $4.2M, -18% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $3.5M, -40% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $2.2M, -3.6% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $3.9M, +166% on a year earlier; public on 8 May 2024
Quarter ended 30 Jun 2024: $1.7M, -59% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.9M, -18% on a year earlier; public on 6 Nov 2024
Quarter ended 31 Dec 2024: $3.1M, +37% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $3.5M, -9.8% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $4.8M, +176% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.8M, -1.9% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $2.4M, -22% on a year earlier; public on 28 Feb 2026
Quarter ended 31 Mar 2026: $3.1M, -14% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $2.2M, -54% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $2.2M, -23% on a year earlier; public on 7 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 71; public on 14 Feb 2022
31 Mar 2022 report: 73; public on 16 May 2022
30 Jun 2022 report: 81; public on 15 Aug 2022
30 Sep 2022 report: 81; public on 14 Nov 2022
31 Dec 2022 report: 101; public on 14 Feb 2023
31 Mar 2023 report: 117; public on 15 May 2023
30 Jun 2023 report: 127; public on 14 Aug 2023
30 Sep 2023 report: 113; public on 14 Nov 2023
31 Dec 2023 report: 120; public on 14 Feb 2024
31 Mar 2024 report: 123; public on 15 May 2024
30 Jun 2024 report: 114; public on 14 Aug 2024
30 Sep 2024 report: 127; public on 14 Nov 2024
31 Dec 2024 report: 131; public on 14 Feb 2025
31 Mar 2025 report: 135; public on 15 May 2025
30 Jun 2025 report: 119; public on 14 Aug 2025
30 Sep 2025 report: 113; public on 14 Nov 2025
31 Dec 2025 report: 110; public on 17 Feb 2026
31 Mar 2026 report: 112; public on 15 May 2026
30 Jun 2026 report: 115; public on 14 Aug 2026
30 Sep 2026 report: 114; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $33K published
Month from 1 Feb 2022: $150K published
Month from 1 Mar 2022: $27K published
Month from 1 Apr 2022: $10K published
Month from 1 May 2022: $25K published
Month from 1 Jun 2022: $21K published
Month from 1 Jul 2022: $14K published
Month from 1 Sep 2022: $36K published
Month from 1 Nov 2022: $12K published
Month from 1 Jan 2023: $12K published
Month from 1 Feb 2023: $10K published
Month from 1 Mar 2023: $67K published
Month from 1 Apr 2023: $58K published
Month from 1 May 2023: $28K published
Month from 1 Jun 2023: $22K published
Month from 1 Jul 2023: $26K published
Month from 1 Aug 2023: $22K published
Month from 1 Sep 2023: $59K published
Month from 1 Oct 2023: $78K published
Month from 1 Nov 2023: $10K published
Month from 1 Dec 2023: $112K published
Month from 1 Jan 2024: $58K published
Month from 1 Feb 2024: $95K published
Month from 1 Mar 2024: $24K published
Month from 1 Apr 2024: $61K published
Month from 1 May 2024: $64K published
Month from 1 Jun 2024: $99K published
Month from 1 Jul 2024: $45K published
Month from 1 Aug 2024: $57K published
Month from 1 Sep 2024: $115K published
Month from 1 Oct 2024: $90K published
Month from 1 Nov 2024: $43K published
Month from 1 Dec 2024: $39K published
Month from 1 Jan 2025: $89K published
Month from 1 Feb 2025: $95K published
Month from 1 Mar 2025: $100K published
Month from 1 Apr 2025: $86K published
Month from 1 May 2025: $47K published
Month from 1 Jun 2025: $64K published
Month from 1 Jul 2025: $315 published
Month from 1 Aug 2025: -$116K published
Month from 1 Oct 2025: -$14K published
Month from 1 Jan 2026: $15K published
Month from 1 Sep 2026: $2K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $2.2M (30 Sep 2026), 27% below its normal quarter of $3.0M; higher than 44% of its own history.
  • Insider net buying (open market): Insiders bought a net $1.4M in the last 12 months (the 12 months before: $125K).
  • Revenue per quarter: Revenue $48.3M in the latest quarter, -3.9% on a year earlier.
  • Capital spending per quarter: Capital spending $2.2M in the latest quarter, -23% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

No trades in the last 90 days; the latest was filed 24 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
24 Aug 2026John T. TreaceChief Executive OfficerBuy55,944$4.41$247KForm 4
11 Jun 2026John T. TreaceChief Executive OfficerBuy52,317$4.03$211KForm 4
1 Jun 2026John T. TreaceChief Executive OfficerBuy50,000$3.56$178KForm 4
28 May 2026John T. TreaceChief Executive OfficerBuy115,520$2.95$340KForm 4
14 May 2026John T. TreaceChief Executive OfficerBuy153,763$2.44$376KForm 4
19 Mar 2025Sean F. ScanlanChief Innovation OfficerSellplanned in advance (10b5-1); after exercising options50,000$7.97$398KForm 4
4 Mar 2025John T. TreaceChief Executive OfficerBuy60,000$8.73$524KForm 4
17 Sep 2024John T. TreaceChief Executive OfficerBuy50,000$5.31$266KForm 4

114 institutions reported shares at the end of Q3 2026, 49% of the shares outstanding; 16 opened a position, 15 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Armistice Capital, LLC6.4M9.71%$28.3MNo change
Gagnon Securities LLC3.4M5.21%$15.2M+386K+13%
Bank of America Corp3.3M4.98%$14.5M-40K-1.2%
Vanguard Capital Management LLC2.1M3.14%$9.1M+30K+1.5%
Gagnon Advisors, LLC1.5M2.34%$6.8MNo change
Acadian Asset Management LLC1.4M2.07%+426K+46%
BlackRock, Inc.1.3M2.00%$5.8M-70K-5.0%
Millennium Management LLC1.2M1.90%$5.5M+508K+69%
Marshall Wace, LLP1.2M1.90%$5.5M-82K-6.2%
CIBC Bancorp USA Inc.1.2M1.85%$5.4M-1240%

Company events

All 17 company events

In 12 months: 1 major agreement, 1 agreement ended, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
9 Apr 2026Director or officer change8-K
18 Dec 2025Signed a major agreement; A major agreement endedSame filing: took on new debt, changed shareholder rights8-K
6 Nov 2025Director or officer change8-K
7 Apr 2025Director or officer change8-K
13 Jun 2023Completed an acquisition or asset sale8-K
23 Feb 2023Director or officer change8-K
10 Feb 2023Signed a major agreement8-K
27 Sep 2022Director or officer change8-K

The 5 newest of 81 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

5 Mar 2024confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Treace Medical Concepts (TMCI): had 2.8M shares sold short in the 31 Jan 2024 report, 1.7× the same report last year, while it reported revenue of $62.2M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

  • Short interest and volume: Short interest spike, became public on 10 Feb 2024
  • Financials: Quarterly revenue change, became public on 5 Mar 2024
  • Short interest and volume: Short interest spike, became public on 28 Feb 2024
2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M
The 31 Jan 2024 report against the 24 reports before it. this reportearliernormal: 1.5M
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 10 Feb 2024

Treace Medical Concepts had 2.8M shares sold short in the 31 Jan 2024 report, 1.7× the same report last year.

This period
2.8M (the 31 Jan 2024 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
258K
How far from its usual level
+3.6
Same report last year
1.6M
History used
1,006 days
2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M
the 31 Jan 2024 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 5 Mar 2024

Treace Medical Concepts reported revenue of $62.2M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

This period
$62.2M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$37.1M
Typical spread (median absolute deviation)
$5.0M
How far from its usual level
+3.4
Same quarter last year
$49.8M
History used
1,370 days
2021-12-31: $33.4M2022-03-31: $29.0M2022-06-30: $30.0M2022-09-30: $33.1M2022-12-31: $49.8M2023-03-31: $42.2M2023-06-30: $42.0M2023-09-30: $40.8M2023-12-31: $62.2M
the quarter ended 31 Dec 20238 earlier quartersnormal: $37.1M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 28 Feb 2024

Treace Medical Concepts had 2.9M shares sold short in the 15 Feb 2024 report, 2.7× the same report last year.

This period
2.9M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
1.5M
Typical spread (median absolute deviation)
265K
How far from its usual level
+3.6
Same report last year
1.1M
History used
1,021 days
2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M2024-02-15: 2.9M
the 15 Feb 2024 report24 earlier reportsnormal: 1.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

22 Nov 2022confirmed

Confirmed across sources Insiders and Filings + Financials

Treace Medical Concepts (TMCI): spent $5.9M on capital projects in the quarter ended 30 Sep 2022, 6.2× the same quarter last year, while it had 3 insiders buy $664K of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity within 6 days.

  • Financials: Quarterly capital spending jump, became public on 15 Nov 2022
  • Insiders: Clustered insider buying, became public on 22 Nov 2022
2020-09-30: $58K2020-12-31: $88K2021-03-31: $196K2021-06-30: $670K2021-09-30: $939K2021-12-31: $900K2022-03-31: $1.5M2022-06-30: $5.2M2022-09-30: $5.9M
The quarter ended 30 Sep 2022 against the 8 quarters before it. this quarterearliernormal: $785K
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 15 Nov 2022

Treace Medical Concepts spent $5.9M on capital projects in the quarter ended 30 Sep 2022, 6.2× the same quarter last year.

This period
$5.9M (the quarter ended 30 Sep 2022)
Normal quarter (median of 8 earlier)
$785K
Typical spread (median absolute deviation)
$642K
How far from its usual level
+5.1
Same quarter last year
$939K
History used
913 days
2020-09-30: $58K2020-12-31: $88K2021-03-31: $196K2021-06-30: $670K2021-09-30: $939K2021-12-31: $900K2022-03-31: $1.5M2022-06-30: $5.2M2022-09-30: $5.9M
the quarter ended 30 Sep 20228 earlier quartersnormal: $785K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Insiders: Clustered insider buying became public on 22 Nov 2022

Treace Medical Concepts had 3 insiders buy $664K of its shares on the open market within 30 days (4 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
4
Total bought
$664K
Window
23 Oct 2022 to 22 Nov 2022

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Aug 2022confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Treace Medical Concepts (TMCI): had 2.3M shares sold short in the 15 Jul 2022 report, 3.3× the same report last year, while it spent $5.2M on capital projects in the quarter ended 30 Jun 2022, 7.7× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 13 Jul 2022
  • Short interest and volume: Short interest spike, became public on 27 Jul 2022
  • Financials: Quarterly capital spending jump, became public on 16 Aug 2022
2021-06-30: 941K2021-07-15: 692K2021-07-30: 631K2021-08-13: 539K2021-08-31: 490K2021-09-15: 562K2021-09-30: 661K2021-10-15: 901K2021-10-29: 453K2021-11-15: 388K2021-11-30: 416K2021-12-15: 630K2022-01-14: 748K2022-01-31: 697K2022-02-15: 1.0M2022-02-28: 839K2022-03-15: 990K2022-03-31: 1.0M2022-04-14: 1.2M2022-04-29: 1.3M2022-05-13: 1.6M2022-05-31: 1.5M2022-06-15: 1.6M2022-06-30: 2.0M2022-07-15: 2.3M
The 15 Jul 2022 report against the 24 reports before it. this reportearliernormal: 794K
See the evidence (3 changes)

Short interest and volume: Short interest spike became public on 13 Jul 2022

Treace Medical Concepts had 2.0M shares sold short in the 30 Jun 2022 report, 2.2× the same report last year.

This period
2.0M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
722K
Typical spread (median absolute deviation)
250K
How far from its usual level
+3.5
Same report last year
941K
History used
426 days
2021-06-15: 234K2021-06-30: 941K2021-07-15: 692K2021-07-30: 631K2021-08-13: 539K2021-08-31: 490K2021-09-15: 562K2021-09-30: 661K2021-10-15: 901K2021-10-29: 453K2021-11-15: 388K2021-11-30: 416K2021-12-15: 630K2022-01-14: 748K2022-01-31: 697K2022-02-15: 1.0M2022-02-28: 839K2022-03-15: 990K2022-03-31: 1.0M2022-04-14: 1.2M2022-04-29: 1.3M2022-05-13: 1.6M2022-05-31: 1.5M2022-06-15: 1.6M2022-06-30: 2.0M
the 30 Jun 2022 report24 earlier reportsnormal: 722K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Jul 2022

Treace Medical Concepts had 2.3M shares sold short in the 15 Jul 2022 report, 3.3× the same report last year.

This period
2.3M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
794K
Typical spread (median absolute deviation)
243K
How far from its usual level
+4.1
Same report last year
692K
History used
441 days
2021-06-30: 941K2021-07-15: 692K2021-07-30: 631K2021-08-13: 539K2021-08-31: 490K2021-09-15: 562K2021-09-30: 661K2021-10-15: 901K2021-10-29: 453K2021-11-15: 388K2021-11-30: 416K2021-12-15: 630K2022-01-14: 748K2022-01-31: 697K2022-02-15: 1.0M2022-02-28: 839K2022-03-15: 990K2022-03-31: 1.0M2022-04-14: 1.2M2022-04-29: 1.3M2022-05-13: 1.6M2022-05-31: 1.5M2022-06-15: 1.6M2022-06-30: 2.0M2022-07-15: 2.3M
the 15 Jul 2022 report24 earlier reportsnormal: 794K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly capital spending jump became public on 16 Aug 2022

Treace Medical Concepts spent $5.2M on capital projects in the quarter ended 30 Jun 2022, 7.7× the same quarter last year.

This period
$5.2M (the quarter ended 30 Jun 2022)
Normal quarter (median of 8 earlier)
$460K
Typical spread (median absolute deviation)
$386K
How far from its usual level
+4.7
Same quarter last year
$670K
History used
821 days
2020-06-30: $249K2020-09-30: $58K2020-12-31: $88K2021-03-31: $196K2021-06-30: $670K2021-09-30: $939K2021-12-31: $900K2022-03-31: $1.5M2022-06-30: $5.2M
the quarter ended 30 Jun 20228 earlier quartersnormal: $460K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 25 Aug 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 55,944 shares of TMCI ($246,841) (dated 24 Aug 2026)

  2. 13 Jun 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 24,606 shares of TMCI ($99,114) [amended] (dated 12 Jun 2026)

  3. 12 Jun 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 52,317 shares of TMCI ($210,772) (dated 11 Jun 2026)

  4. 2 Jun 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 50,000 shares of TMCI ($178,000) (dated 1 Jun 2026)

  5. 29 May 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 115,520 shares of TMCI ($340,362) (dated 28 May 2026)

  6. 15 May 2026Insiders record

    Treace John T. (Chief Executive Officer) bought 153,763 shares of TMCI ($375,667) (dated 14 May 2026)

  7. 9 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 9 Apr 2026Filings record

    Director or officer change

  9. 18 Dec 2025Filings record

    A major agreement ended

  10. 6 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 6 Nov 2025Filings record

    Director or officer change

  12. 7 Apr 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 7 Apr 2025Filings record

    Director or officer change

  14. 5 Mar 2025Insiders record

    Treace John T. (Chief Executive Officer) bought 60,000 shares of TMCI ($523,800) (dated 4 Mar 2025)

  15. 18 Sep 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 50,000 shares of TMCI ($265,500) (dated 17 Sep 2024)

  16. 20 Aug 2024Insiders record

    TREACE JAMES T (director) bought 84,000 shares of TMCI ($500,640) (dated 19 Aug 2024)

  17. 16 Aug 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 85,000 shares of TMCI ($510,000) (dated 15 Aug 2024)

  18. 12 Jun 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 45,000 shares of TMCI ($264,600) (dated 11 Jun 2024)

  19. 4 Jun 2024Insiders record

    TREACE JAMES T (director) bought 25,000 shares of TMCI ($151,250) (dated 3 Jun 2024)

  20. 31 May 2024Insiders record

    TREACE JAMES T (director) bought 25,000 shares of TMCI ($130,000) (dated 30 May 2024)

  21. 30 May 2024Insiders record

    TREACE JAMES T (director) bought 50,000 shares of TMCI ($253,500) (dated 29 May 2024)

  22. 29 May 2024Insiders record

    MOTT RICHARD W (director) bought 18,000 shares of TMCI ($93,420) (dated 28 May 2024)

  23. 24 May 2024Insiders record

    MOTT RICHARD W (director) bought 12,100 shares of TMCI ($60,379) (dated 23 May 2024)

  24. 21 May 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 100,000 shares of TMCI ($556,000) (dated 20 May 2024)

  25. 15 May 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 150,000 shares of TMCI ($768,000) (dated 14 May 2024)

  26. 15 May 2024Insiders record

    Kiernan Jane E (director) bought 19,356 shares of TMCI ($100,071) (dated 14 May 2024)

  27. 14 May 2024Insiders change

    had 5 insiders buy $3.7M of its shares on the open market within 30 days (5 filings).

    Who bought: Treace James T, Jain Deepti, Mott Richard W, Bakewell John K and 1 more.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $3.7M
    Window
    14 Apr 2024 to 14 May 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  28. 14 May 2024Insiders record

    Treace John T. (Chief Executive Officer) bought 300,000 shares of TMCI ($1.4M) (dated 13 May 2024)

  29. 14 May 2024Insiders record

    BAKEWELL JOHN K (director) bought 130,000 shares of TMCI ($594,100) (dated 13 May 2024)

  30. 14 May 2024Insiders record

    MOTT RICHARD W (director) bought 120,000 shares of TMCI ($541,408) (dated 13 May 2024)

  31. 14 May 2024Insiders record

    Jain Deepti (director) bought 25,000 shares of TMCI ($112,500) (dated 13 May 2024)

  32. 14 May 2024Insiders record

    TREACE JAMES T (director) bought 228,000 shares of TMCI ($1.0M) (dated 13 May 2024)

  33. 5 Mar 2024several at once

    had 2.8M shares sold short in the 31 Jan 2024 report, 1.7× the same report last year, while it reported revenue of $62.2M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year. Two unrelated kinds of activity within 21 days.

    See the evidence (3 changes)

    Short interest and volume: Short interest spike became public on 10 Feb 2024

    Treace Medical Concepts had 2.8M shares sold short in the 31 Jan 2024 report, 1.7× the same report last year.

    This period
    2.8M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +3.6
    Same report last year
    1.6M
    History used
    1,006 days
    2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M
    the 31 Jan 2024 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 5 Mar 2024

    Treace Medical Concepts reported revenue of $62.2M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    This period
    $62.2M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $37.1M
    Typical spread (median absolute deviation)
    $5.0M
    How far from its usual level
    +3.4
    Same quarter last year
    $49.8M
    History used
    1,370 days
    2021-12-31: $33.4M2022-03-31: $29.0M2022-06-30: $30.0M2022-09-30: $33.1M2022-12-31: $49.8M2023-03-31: $42.2M2023-06-30: $42.0M2023-09-30: $40.8M2023-12-31: $62.2M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $37.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 28 Feb 2024

    Treace Medical Concepts had 2.9M shares sold short in the 15 Feb 2024 report, 2.7× the same report last year.

    This period
    2.9M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    265K
    How far from its usual level
    +3.6
    Same report last year
    1.1M
    History used
    1,021 days
    2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M2024-02-15: 2.9M
    the 15 Feb 2024 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  34. 5 Mar 2024Financials change

    reported revenue of $62.2M for the quarter ended 31 Dec 2023, 1.3× the same quarter last year.

    Same quarter last year: $49.8M; its normal quarter is $37.1M.

    See the evidence
    This period
    $62.2M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $37.1M
    Typical spread (median absolute deviation)
    $5.0M
    How far from its usual level
    +3.4
    Same quarter last year
    $49.8M
    History used
    1,370 days
    2021-12-31: $33.4M2022-03-31: $29.0M2022-06-30: $30.0M2022-09-30: $33.1M2022-12-31: $49.8M2023-03-31: $42.2M2023-06-30: $42.0M2023-09-30: $40.8M2023-12-31: $62.2M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $37.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  35. 28 Feb 2024Short interest and volume change

    had 2.9M shares sold short in the 15 Feb 2024 report, 2.7× the same report last year.

    Same report last year: 1.1M; its normal report is 1.5M.

    See the evidence
    This period
    2.9M (the 15 Feb 2024 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    265K
    How far from its usual level
    +3.6
    Same report last year
    1.1M
    History used
    1,021 days
    2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M2024-02-15: 2.9M
    the 15 Feb 2024 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 10 Feb 2024Short interest and volume change

    had 2.8M shares sold short in the 31 Jan 2024 report, 1.7× the same report last year.

    Same report last year: 1.6M; its normal report is 1.5M.

    See the evidence
    This period
    2.8M (the 31 Jan 2024 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +3.6
    Same report last year
    1.6M
    History used
    1,006 days
    2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M2024-01-12: 2.6M2024-01-31: 2.8M
    the 31 Jan 2024 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 11 Jan 2024Short interest and volume change

    had 3.0M shares sold short in the 29 Dec 2023 report, 1.7× the same report last year.

    Same report last year: 1.8M; its normal report is 1.5M.

    See the evidence
    This period
    3.0M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +4.0
    Same report last year
    1.8M
    History used
    973 days
    2022-12-30: 1.8M2023-01-13: 1.8M2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M2023-11-30: 2.5M2023-12-15: 2.8M2023-12-29: 3.0M
    the 29 Dec 2023 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 28 Nov 2023Short interest and volume change

    had 3.8M shares sold short in the 15 Nov 2023 report, 1.4× the same report last year.

    Same report last year: 2.7M; its normal report is 1.5M.

    See the evidence
    This period
    3.8M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +6.0
    Same report last year
    2.7M
    History used
    929 days
    2022-11-15: 2.7M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 1.8M2023-01-13: 1.8M2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M2023-11-15: 3.8M
    the 15 Nov 2023 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 10 Nov 2023Short interest and volume change

    had 3.9M shares sold short in the 31 Oct 2023 report, 1.5× the same report last year.

    Same report last year: 2.6M; its normal report is 1.5M.

    See the evidence
    This period
    3.9M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    1.5M
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +6.3
    Same report last year
    2.6M
    History used
    914 days
    2022-10-31: 2.6M2022-11-15: 2.7M2022-11-30: 2.0M2022-12-15: 2.0M2022-12-30: 1.8M2023-01-13: 1.8M2023-01-31: 1.6M2023-02-15: 1.1M2023-02-28: 1.0M2023-03-15: 1.2M2023-03-31: 1.5M2023-04-14: 1.7M2023-04-28: 1.3M2023-05-15: 1.4M2023-05-31: 1.4M2023-06-15: 1.2M2023-06-30: 1.2M2023-07-14: 1.2M2023-07-31: 1.2M2023-08-15: 1.2M2023-08-31: 1.3M2023-09-15: 1.7M2023-09-29: 2.0M2023-10-13: 2.1M2023-10-31: 3.9M
    the 31 Oct 2023 report24 earlier reportsnormal: 1.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 13 Jun 2023Filings record

    Completed an acquisition or asset sale

Showing the newest 40 of 71 entries; narrow the window or the kind of data to see older ones.

Not listed: 157 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001630627
Ticker
TMCI
Domain
treace.com
Hq location
FL|PONTE VEDRA|32081 (1 unverified)
Name
Treace Medical Concepts, Inc.
Uei
LM4LSM8ULRM4
Wikipedia
Treace Medical Concepts
  • SEC Form 13F institutional holdings198 data points30 Jun 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)74 records9 Feb 2017 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)496 data points31 Dec 2018 to 30 Oct 2026
  • SEC Form 4 insider transactions132 records, 400 data points29 Apr 2021 to 24 Aug 2026
  • FINRA short interest (twice monthly)395 data points30 Apr 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2806 data points23 Apr 2021 to 20 Nov 2026
  • USASpending.gov federal awards726 data points16 May 2017 to 1 Sep 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026